The Oncobiologics Team

Oncobiologics was formed by a team of accomplished scientists and engineers with over 100 years of experience in major pharmaceutical and biotech companies. The team brings senior management and technical experience from top-tier organizations, including; Amgen, Genentech, Eli Lilly, Bristol-Myers Squibb, Pfizer, Bayer, Merck, Johnson & Johnson, Schering-Plough and Medarex.

Oncobiologics combines the world-class know-how of leading discovery and development scientists with the agile, innovative culture of a start-up. We have also developed an expert advisory team and partnerships with leading institutions to complement our capabilities.

Pankaj Mohan, Ph.D.

Dr. Mohan founded Oncobiologics in 2011 after a distinguished 20+ year career in the global biopharmaceutical industry.  Most recently, Dr. Mohan headed  Business Operations and Portfolio Management for a division of Bristol-Myers Squibb, where he was instrumental in expanding the business’ biologics pipeline.  He also held prior positions at Genentech and Eli Lilly and Company, where he led various bioprocess engineering functions.   Dr. Mohan also served as Assistant Professor (Lecturer/Fellow), at the Advanced Centre for Biochemical Engineering  at University College London.

During his career, Dr. Mohan played an important role in the development and manufacture of multiple blockbuster biopharmaceutical drugs. He planned, initiated and led a state of the art biologics R&D organization, and most recently led the acquisition of small biotech companies and multiple biologics molecule assets.

He earned his Ph.D. in Biochemical  Engineering at the School of Chemical Engineering, University of Birmingham, Birmingham, United Kingdom;  his MBA specializing in Finance Management from Middlesex University Business School, London, United Kingdom, and his Bachelor of Chemical Engineering at the Indian Institute of Technology in India.  Dr. Mohan also participated in the Executive Management program at the Fuqua School of Business, Duke University.

Dr. Mohan has authored a book on Pharmaceutical Manufacturing published by McGraw Hill and is the author of more than 30 publications.

John K. Cini. Ph.D.

Dr. Cini is Vice President of Discovery & Developmental Sciences and is responsible for leading the company's discovery and development programs for novel cancer and immune disease therapies. Prior to joining Oncobiologics, Dr. Cini held senior scientific and technical leadership positions at Medarex (acquired by Bristol-Myers Squibb in 2010). Previous positions included scientific roles at Johnson & Johnson, Alexion, and Bayer. He is the holder of several product and formulation patents and has led several successful molecules through development and commercialization including immuno-oncology products.  Dr. Cini earned his Ph.D. in Biochemistry from the University of North Texas.

Scott Gangloff

Scott joined Oncobiologics in 2011 with more than 15 years of experience in biopharmaceutical process development and cGMP manufacturing. He previously spent over 12 years at Bristol-Myers Squibb, where he led multiple biologics programs through process development, scale-up, clinical manufacturing, and transfer to commercial manufacturing. Scott also spent time with Jacobs Engineering as a Process Engineer. Scott brings an accomplished track record of leadership in developing and scaling-up processes designed for production of mAbs, fAbs, and PEGylated proteins through both mammalian and microbial expression systems. By integrating process development with clinical manufacturing, an emphasis on process design for manufacture enables rapid progression of molecules from DNA to FIH. Scott earned his Master’s in Chemical Engineering from Lehigh University and his Bachelors in Chemical Engineering from Villanova University.

Donald J. Griffith, C.P.A.

Don Griffith brings to Oncobiologics more than 30 years of experience in finance and accounting, including a partner position in the New Jersey accounting firm of Stolz & Griffith. Previously, his  roles included CFO and financial leadership positions  and more than 10 years in corporate finance with Exxon corporation. Don is a member of New Jersey Society of CPAs and the American Institute of CPAs.

Stephen J. McAndrew, Ph.D.

Vice President, Business Development

Dr. McAndrew is Vice President of Business Development and is responsible for the company’s revenue growth strategy and initiatives, establishing and managing all collaborative research and commercial product partnerships, and sourcing selected investment opportunities.

Prior to joining Oncobiologics, Dr. McAndrew served as Vice President, Business Development for Xenogen Biosciences, Caliper Life Sciences and Taconic Biosciences, where he was responsible for managing new business development, licensing and marketing functions. Previously, he served as Vice President, Pharmaceutical Business Development for Lexicon Pharmaceuticals and Director, Biotechnology Licensing for Bristol-Myers Squibb Company.  In each case, he was responsible for identifying, evaluating, negotiating and managing numerous preclinical compound collaborations and innovative platform technology alliances.  Prior to transitioning to Business Development/Licensing roles, Dr. McAndrew led applied research programs within Discovery-Oncology at Bristol-Myers Squibb, and exploratory research in the Roche Institute of Molecular Biology at Hoffmann La-Roche.

Dr. McAndrew earned his Ph.D. in Cellular and Molecular Biology from Ohio University, his Masters of Science in Molecular Genetics from SUNY at Albany and his Bachelors of Science from SUNY at Oswego.

Richard C. Gregory

Rick Gregory brings more than 20 years of strategic marketing experience to Oncobiologics. As an independent consultant, he has led dozens of life sciences strategy and execution engagements with leading firms such as GE Healthcare Life Sciences, Oncogene Sciences (OSI, now part of Astellas), CARR-Centritech, Xcellerex, Natrix Separations, FTS Systems, Sepracor, VWR International and Mayo Medical Laboratories.  He is also the author of the bestselling business book, The Dollarization Discipline, published by John Wiley & Sons in 2004.  Rick earned his B.A. in Economics from Amherst College.